Page 2 - Previously Treated News Today

2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4%* and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of...

Avutometinib + Sotorasib Combination Demonstrated Preliminary Efficacy with Confirmed Responses in both KRAS G12C Inhibitor Resistant and Naïve PatientsNo New Safety Signals Observed in Combination; Most Treatment-Related Adverse Events Mild to ModerateEnrollment of Patients Naïve to or Previously Treated with a KRA...

1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months). 2. Drug-related interstitial lung disease was more common with patients receiving trastuzumab deruxtecan. Evidence Rating Level: 1 (Excellent) Study Rundown: A large proportion of breast cancers are characterized by overexpression of HER2 receptors. While first-line therapy for

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global...

-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million- -PADCEV® Granted FDA Accelerated Approval in Combination with KEYTRUDA® as First-Line Treatment for... | April 27, 2023

-Total Revenues of $2.0 Billion in 2022, Including 23 Percent Annual Increase in Total Net Product Sales to $1.7 Billion--TUKYSA Granted FDA Accelerated Approval for Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer--ADCETRIS Received Pediatric Indication with FDA Approval for Children wit...

Latest news on Cancer Treatment including updates on radiotherapy, chemotherapy, immunotherapy, funding, trials and developments.

Enhertu Approved by Health Canada as the First HER2-Directed Therapy for Patients with HER2-Low Metastatic Breast Cancer - read this article along with other careers information, tips and advice on BioSpace

Investegate announcements from AstraZeneca PLC, Enhertu recommended for EU approval in HER2-low BC

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...